What is Indivior Pharmaceuticals Inc.'s earnings per share (EPS)?

Indivior Pharmaceuticals Inc. (INDV) reported diluted earnings per share of $1.64 for fiscal year 2025. This represents a 3180.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Indivior Pharmaceuticals Inc. Financials

INDV

FY2025 annual

Revenue $1.2B +4.3% YoY

Net Income $210.0M +2900.0% YoY

EPS (Diluted) $1.64 +3180.0% YoY

Free Cash Flow -$93.0M -1428.6% YoY

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

Indivior Pharmaceuticals Inc. (INDV) reported $1.2B in revenue for fiscal year 2025, up 4.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI INDV FY2025 2026-08-03

Profitability rebounded through below-gross-profit operating leverage, but cash conversion and liquidity weakened as FY2025 closed.

From FY2023 to FY2025, operating margin swung from -13.9% to 21.2% even with only modest top-line growth and a lower gross margin, so the turnaround came mainly from below-gross-line expense structure rather than richer unit economics. That accounting rebound did not convert to cash: FY2025 net income reached $210M, yet operating cash flow was -$27M and free cash flow remained negative after heavier reinvestment.

The company still runs with negative equity of -$98M because liabilities exceed assets. But that deficit narrowed sharply from -$337M, so balance-sheet repair is happening through retained earnings even though an equity cushion has not been rebuilt.

Liquidity tightened as the current ratio fell to 0.7x, leaving current liabilities ahead of current assets and making working capital a more active constraint. Cash also dropped to $195M, and higher capital spending kept free cash flow negative, so FY2025 ended with less short-term flexibility even as long-term debt edged down.

Financial Health Signals

Financial Health Score 45/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Indivior Pharmaceuticals Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Indivior Pharmaceuticals Inc. has an operating margin of 21.1%, meaning the company retains $21 of operating profit per $100 of revenue. This results in a moderate score of 48/100, indicating healthy but not exceptional operating efficiency. This is up from 3.2% the prior year.

Growth

Indivior Pharmaceuticals Inc.'s revenue grew a modest 4.3% year-over-year to $1.2B. This slow but positive growth earns a score of 55/100.

Leverage

Liquidity

Indivior Pharmaceuticals Inc.'s current ratio of 0.71 is below the typical benchmark, resulting in a score of 9/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

Indivior Pharmaceuticals Inc.'s operations used $27.0M of cash, and capex of $66.0M added to the outflow, for a free cash flow shortfall of $93.0M. This results in a cash flow score of 16/100.

Returns

Altman Z-Score Safe

3.21

Indivior Pharmaceuticals Inc. scores 3.21, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($4.4B) relative to total liabilities ($1.3B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

Indivior Pharmaceuticals Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

$0.13used

For every $1 of reported earnings, Indivior Pharmaceuticals Inc. used $0.13 of operating cash (-$27.0M OCF vs $210.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Interest Coverage Safe

6.89x

Indivior Pharmaceuticals Inc. earns $6.89 in operating income for every $1 of interest expense ($262.0M vs $38.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.2B

YoY+4.3%

Indivior Pharmaceuticals Inc. generated $1.2B in revenue in fiscal year 2025. This represents an increase of 4.3% from the prior year.

EBITDA

$272.0M

YoY+403.7%

Indivior Pharmaceuticals Inc.'s EBITDA was $272.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 403.7% from the prior year.

Net Income

$210.0M

YoY+2900.0%

Indivior Pharmaceuticals Inc. reported $210.0M in net income in fiscal year 2025. This represents an increase of 2900.0% from the prior year.

EPS (Diluted)

$1.64

YoY+3180.0%

Indivior Pharmaceuticals Inc. earned $1.64 per diluted share (EPS) in fiscal year 2025. This represents an increase of 3180.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$93.0M

YoY-1428.6%

Indivior Pharmaceuticals Inc. recorded an outflow of $93.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 1428.6% from the prior year.

Cash & Debt

$195.0M

YoY-38.9%

Indivior Pharmaceuticals Inc. held $195.0M in cash against $290.0M in long-term debt as of fiscal year 2025.

Shares Outstanding

125M

Indivior Pharmaceuticals Inc. had 125M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

80.2%

YoY-0.3pp

Indivior Pharmaceuticals Inc.'s gross margin was 80.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.3 percentage points from the prior year.

Operating Margin

21.1%

YoY+17.9pp

Indivior Pharmaceuticals Inc.'s operating margin was 21.1% in fiscal year 2025, reflecting core business profitability. This is up 17.9 percentage points from the prior year.

Net Margin

17.0%

YoY+16.4pp

Indivior Pharmaceuticals Inc.'s net profit margin was 17.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 16.4 percentage points from the prior year.

Return on Equity

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$97.0M

YoY-9.3%

Indivior Pharmaceuticals Inc. invested $97.0M in research and development in fiscal year 2025. This represents a decrease of 9.3% from the prior year.

Share Buybacks

$11.0M

YoY-93.6%

Indivior Pharmaceuticals Inc. spent $11.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 93.6% from the prior year.

Capital Expenditures

$66.0M

YoY+127.6%

Indivior Pharmaceuticals Inc. invested $66.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 127.6% from the prior year.

INDV Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

INDV annual income statement

Metric	TTM	FY25	FY24	FY23	FY22
Revenue	$1.3B	$1.2B+4.3%	$1.2B+8.7%	$1.1B+21.3%	$901.0M
Cost of Revenue	$240.0M	$246.0M+6.5%	$231.0M+32.8%	$174.0M+15.2%	$151.0M
Gross Profit	$1.1B	$994.0M+3.9%	$957.0M+4.1%	$919.0M+22.7%	$749.0M
R&D Expenses	$82.0M	$97.0M-9.3%	$107.0M-7.8%	$116.0M+56.8%	$74.0M
SG&A Expenses	$589.0M	$634.0M+3.6%	$612.0M+8.3%	$565.0M+21.2%	$466.0M
Operating Income	$421.0M	$262.0M+589.5%	$38.0M+125.0%	-$152.0M-97.4%	-$77.0M
Interest Expense	$29.0M	$38.0M+26.7%	$30.0M+11.1%	$27.0M+42.1%	$19.0M
Income Tax	$38.0M	$29.0M+123.1%	$13.0M+168.4%	-$19.0M+55.8%	-$43.0M
Net Income	$356.0M	$210.0M+2900.0%	$7.0M+105.6%	-$126.0M-200.0%	-$42.0M
EPS (Diluted)	—	$1.64+3180.0%	$0.05+105.4%	-$0.92-206.7%	-$0.30

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$343.0M+8.2%	$317.0M-11.2%	$357.0M+13.7%	$314.0M+4.0%	$302.0M+13.5%	$266.0M-10.7%	$298.0M-2.9%	$307.0M
Cost of Revenue	$50.0M+25.0%	$40.0M-40.3%	$67.0M-19.3%	$83.0M+59.6%	$52.0M+18.2%	$44.0M-8.3%	$48.0M-27.3%	$66.0M
Gross Profit	$294.0M+6.1%	$277.0M-5.5%	$293.0M+27.4%	$230.0M-8.0%	$250.0M+13.1%	$221.0M-11.6%	$250.0M+3.7%	$241.0M
R&D Expenses	$12.0M-25.0%	$16.0M-23.8%	$21.0M-36.4%	$33.0M+57.1%	$21.0M-4.5%	$22.0M-29.0%	$31.0M+40.9%	$22.0M
SG&A Expenses	$122.0M-1.6%	$124.0M-34.0%	$188.0M+21.3%	$155.0M-1.9%	$158.0M+18.8%	$133.0M-24.0%	$175.0M+23.2%	$142.0M
Operating Income	$160.0M+16.8%	$137.0M+69.1%	$81.0M+88.4%	$43.0M-40.3%	$72.0M+9.1%	$66.0M+43.5%	$46.0M+31.4%	$35.0M
Interest Expense	$2.0M-71.4%	$7.0M-36.4%	$11.0M+22.2%	$9.0M0.0%	$9.0M0.0%	$9.0M0.0%	$9.0M+28.6%	$7.0M
Income Tax	$38.0M+46.2%	$26.0M+223.8%	-$21.0M-320.0%	-$5.0M-111.4%	$44.0M+300.0%	$11.0M-35.3%	$17.0M+112.5%	$8.0M
Net Income	$122.0M+37.1%	$89.0M-13.6%	$103.0M+145.2%	$42.0M+133.3%	$18.0M-61.7%	$47.0M+123.8%	$21.0M-4.5%	$22.0M
EPS (Diluted)	$0.98+42.0%	$0.69	N/A	$0.33+135.7%	$0.14-63.2%	$0.38	N/A	$0.16

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

INDV Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

INDV annual balance sheet

Metric	FY25	FY24	FY23	FY22
Total Assets	$1.2B-8.7%	$1.3B-25.1%	$1.8B	N/A
Current Assets	$652.0M-21.2%	$827.0M-34.2%	$1.3B	N/A
Cash & Equivalents	$195.0M-38.9%	$319.0M+0.9%	$316.0M-59.2%	$774.0M
Inventory	$153.0M-8.4%	$167.0M+32.5%	$126.0M	N/A
Accounts Receivable	$253.0M-0.4%	$254.0M0.0%	$254.0M	N/A
Goodwill	$2.0M0.0%	$2.0M-60.0%	$5.0M	N/A
Total Liabilities	$1.3B-21.3%	$1.7B-14.9%	$1.9B	N/A
Current Liabilities	$914.0M-1.1%	$924.0M-27.9%	$1.3B	N/A
Long-Term Debt	$290.0M-7.9%	$315.0M+32.9%	$237.0M	N/A
Total Equity	-$98.0M+70.9%	-$337.0M-83.2%	-$184.0M-1126.7%	-$15.0M
Retained Earnings	-$243.0M+45.1%	-$443.0M-53.8%	-$288.0M	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$1.2B+3.0%	$1.2B-0.3%	$1.2B-15.2%	$1.4B-2.5%	$1.5B+5.6%	$1.4B+4.5%	$1.3B	N/A
Current Assets	$725.0M+8.7%	$667.0M+2.3%	$652.0M-29.3%	$922.0M-3.0%	$951.0M+7.7%	$883.0M+6.8%	$827.0M	N/A
Cash & Equivalents	$222.0M+26.9%	$175.0M-10.3%	$195.0M-56.2%	$445.0M-12.7%	$510.0M+37.1%	$372.0M+16.6%	$319.0M+10.8%	$288.0M
Inventory	$150.0M-1.3%	$152.0M-0.7%	$153.0M-1.3%	$155.0M+4.0%	$149.0M-8.6%	$163.0M-2.4%	$167.0M	N/A
Accounts Receivable	$271.0M-0.7%	$273.0M+7.9%	$253.0M-2.3%	$259.0M+7.9%	$240.0M-1.2%	$243.0M-4.3%	$254.0M	N/A
Goodwill	N/A	N/A	$2.0M	N/A	N/A	N/A	$2.0M	N/A
Total Liabilities	$1.4B+7.5%	$1.3B+3.2%	$1.3B-19.9%	$1.6B-5.0%	$1.7B+3.0%	$1.7B+0.5%	$1.7B	N/A
Current Liabilities	$868.0M+11.4%	$779.0M-14.8%	$914.0M-5.3%	$965.0M-8.6%	$1.1B+5.1%	$1.0B+8.8%	$924.0M	N/A
Long-Term Debt	$487.0M+0.2%	$486.0M+67.6%	$290.0M-4.6%	$304.0M-1.3%	$308.0M-1.0%	$311.0M-1.3%	$315.0M	N/A
Total Equity	-$208.0M-44.4%	-$144.0M-46.9%	-$98.0M+52.7%	-$207.0M+19.5%	-$257.0M+9.8%	-$285.0M+15.4%	-$337.0M-8.7%	-$310.0M
Retained Earnings	-$334.0M-19.3%	-$280.0M-15.2%	-$243.0M+29.8%	-$346.0M+10.8%	-$388.0M+4.4%	-$406.0M+8.4%	-$443.0M	N/A

INDV Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

INDV annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22
Operating Cash Flow	-$40.0M	-$27.0M-175.0%	$36.0M+112.0%	-$300.0M-7400.0%	-$4.0M
Capital Expenditures	$71.0M	$66.0M+127.6%	$29.0M+262.5%	$8.0M+60.0%	$5.0M
Free Cash Flow	-$111.0M	-$93.0M-1428.6%	$7.0M+102.3%	-$308.0M-3322.2%	-$9.0M
Investing Cash Flow	-$71.0M	-$66.0M-195.7%	$69.0M+172.6%	-$95.0M+57.2%	-$222.0M
Financing Cash Flow	-$174.0M	-$30.0M+70.6%	-$102.0M-59.4%	-$64.0M+36.6%	-$101.0M
Share Buybacks	$302.0M	$11.0M-93.6%	$173.0M+424.2%	$33.0M-63.3%	$90.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$229.0M+2644.4%	-$9.0M+95.9%	-$221.0M-466.7%	-$39.0M-124.7%	$158.0M+110.7%	$75.0M+541.2%	-$17.0M-950.0%	$2.0M
Capital Expenditures	$7.0M-65.0%	$20.0M-16.7%	$24.0M+20.0%	$20.0M+17.6%	$17.0M+240.0%	$5.0M-68.8%	$16.0M+128.6%	$7.0M
Free Cash Flow	$222.0M+865.5%	-$29.0M+88.2%	-$245.0M-315.3%	-$59.0M-141.8%	$141.0M+101.4%	$70.0M+312.1%	-$33.0M-560.0%	-$5.0M
Investing Cash Flow	-$8.0M+57.9%	-$19.0M+20.8%	-$24.0M-20.0%	-$20.0M-17.6%	-$17.0M-240.0%	-$5.0M-162.5%	$8.0M-77.1%	$35.0M
Financing Cash Flow	-$173.0M-2571.4%	$7.0M+240.0%	-$5.0M-66.7%	-$3.0M+40.0%	-$5.0M+70.6%	-$17.0M-142.5%	$40.0M+178.4%	-$51.0M
Share Buybacks	$177.0M+41.6%	$125.0M	$0	$0	$0-100.0%	$11.0M-78.0%	$50.0M-3.8%	$52.0M

Not reported in any period shown, so not listed: Dividends Paid.

INDV Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

INDV annual financial ratios

Metric	FY25	FY24	FY23	FY22
Gross Margin	80.2%-0.3pp	80.6%-3.5pp	84.1%+0.9pp	83.1%
Operating Margin	21.1%+17.9pp	3.2%+17.1pp	-13.9%-5.4pp	-8.6%
Net Margin	17.0%+16.4pp	0.6%+12.1pp	-11.5%-6.9pp	-4.7%
Return on Assets	17.5%+17.0pp	0.5%+7.7pp	-7.2%	N/A
Current Ratio	0.71-0.2x	0.90-0.1x	0.98	N/A
FCF Margin	-7.5%-8.1pp	0.6%+28.8pp	-28.2%-27.2pp	-1.0%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	85.7%-1.7pp	87.4%+5.3pp	82.1%+8.8pp	73.3%-9.5pp	82.8%-0.3pp	83.1%-0.8pp	83.9%+5.4pp	78.5%
Operating Margin	46.7%+3.4pp	43.2%+20.5pp	22.7%+9.0pp	13.7%-10.2pp	23.8%-1.0pp	24.8%+9.4pp	15.4%+4.0pp	11.4%
Net Margin	35.6%+7.5pp	28.1%-0.8pp	28.8%+15.5pp	13.4%+7.4pp	6.0%-11.7pp	17.7%+10.6pp	7.0%-0.1pp	7.2%
Return on Assets	9.9%+2.5pp	7.4%-1.1pp	8.6%+5.6pp	3.0%+1.7pp	1.2%-2.2pp	3.4%+1.8pp	1.6%	N/A
Current Ratio	0.840.0x	0.86+0.1x	0.71-0.2x	0.96+0.1x	0.900.0x	0.880.0x	0.90	N/A
FCF Margin	64.7%+73.9pp	-9.2%+59.5pp	-68.6%-49.8pp	-18.8%-65.5pp	46.7%+20.4pp	26.3%+37.4pp	-11.1%-9.4pp	-1.6%

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.

Note: Shareholder equity is negative (-$98.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.71), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Hutchmed (China) Limited HCM

$2.2B

Amneal Pharmaceuticals Inc AMRX

$6.3B

Bausch Health Companies Inc BHC

$2.6B

Supernus Pharma SUPN

$2.8B

Kiniksa Pharmaceuticals International, plc KNSA

$6.3B

Where Indivior Pharmaceuticals Inc. Ranks

Frequently Asked Questions

What is Indivior Pharmaceuticals Inc.'s annual revenue?

Indivior Pharmaceuticals Inc. (INDV) reported $1.2B in total revenue for fiscal year 2025. This represents a 4.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Indivior Pharmaceuticals Inc.'s revenue growing?

Indivior Pharmaceuticals Inc. (INDV) revenue grew by 4.3% year-over-year, from $1.2B to $1.2B in fiscal year 2025.

Is Indivior Pharmaceuticals Inc. profitable?

Yes, Indivior Pharmaceuticals Inc. (INDV) reported a net income of $210.0M in fiscal year 2025, with a net profit margin of 17.0%.

What is Indivior Pharmaceuticals Inc.'s EBITDA?

Indivior Pharmaceuticals Inc. (INDV) had EBITDA of $272.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Indivior Pharmaceuticals Inc. have?

As of fiscal year 2025, Indivior Pharmaceuticals Inc. (INDV) had $195.0M in cash and equivalents against $290.0M in long-term debt.

What is Indivior Pharmaceuticals Inc.'s gross margin?

Indivior Pharmaceuticals Inc. (INDV) had a gross margin of 80.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Indivior Pharmaceuticals Inc.'s operating margin?

Indivior Pharmaceuticals Inc. (INDV) had an operating margin of 21.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Indivior Pharmaceuticals Inc.'s net profit margin?

Indivior Pharmaceuticals Inc. (INDV) had a net profit margin of 17.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Indivior Pharmaceuticals Inc.'s free cash flow?

Indivior Pharmaceuticals Inc. (INDV) recorded an outflow of $93.0M in free cash flow during fiscal year 2025. This represents a -1428.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Indivior Pharmaceuticals Inc.'s operating cash flow?

Indivior Pharmaceuticals Inc. (INDV) recorded an outflow of $27.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Indivior Pharmaceuticals Inc.'s total assets?

Indivior Pharmaceuticals Inc. (INDV) had $1.2B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Indivior Pharmaceuticals Inc.'s capital expenditures?

Indivior Pharmaceuticals Inc. (INDV) invested $66.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Indivior Pharmaceuticals Inc. spend on research and development?

Indivior Pharmaceuticals Inc. (INDV) invested $97.0M in research and development during fiscal year 2025.

Does Indivior Pharmaceuticals Inc. buy back shares?

Yes, Indivior Pharmaceuticals Inc. (INDV) spent $11.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Indivior Pharmaceuticals Inc. have outstanding?

Indivior Pharmaceuticals Inc. (INDV) had 125M shares outstanding as of fiscal year 2025.

What is Indivior Pharmaceuticals Inc.'s current ratio?

Indivior Pharmaceuticals Inc. (INDV) had a current ratio of 0.71 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Indivior Pharmaceuticals Inc.'s return on assets (ROA)?

Indivior Pharmaceuticals Inc. (INDV) had a return on assets of 17.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Indivior Pharmaceuticals Inc.'s cash runway?

Based on fiscal year 2025 data, Indivior Pharmaceuticals Inc. (INDV) had $195.0M in cash against an annual operating cash burn of $27.0M. This gives an estimated cash runway of approximately 87 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Indivior Pharmaceuticals Inc.'s debt-to-equity ratio negative or not reported?

Indivior Pharmaceuticals Inc. (INDV) has negative shareholder equity of -$98.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Indivior Pharmaceuticals Inc.'s Altman Z-Score?

Indivior Pharmaceuticals Inc. (INDV) has an Altman Z-Score of 3.21, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Indivior Pharmaceuticals Inc.'s Piotroski F-Score?

Indivior Pharmaceuticals Inc. (INDV) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Indivior Pharmaceuticals Inc.'s earnings high quality?

For every $1 of reported earnings, Indivior Pharmaceuticals Inc. (INDV) used $0.13 of operating cash (-$27.0M OCF vs $210.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Indivior Pharmaceuticals Inc. cover its interest payments?

Indivior Pharmaceuticals Inc. (INDV) has an interest coverage ratio of 6.89x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Indivior Pharmaceuticals Inc.?

Indivior Pharmaceuticals Inc. (INDV) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.